~~<i id='B95CC08BF8'><strike id='B95CC08BF8'><tt id='B95CC08BF8'><pre id='B95CC08BF8'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

entertainment

author：hotspot 2025-09-02 11:45:40 - browse：77

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： More doctors should go into startup world

leisure time

focus

leisure time

focus

hotspot

focus

YichuanCao/SipaUSAGileadSciencessaidMondayitwillacquireCymaBayTherapeuticsfor$4.3billion,addinganewt

WSS

'Revelatory' study finds a smoking impact that remains after quitting

The new shift in health care is toward less care

Will General Catalyst be the first of many hospital takeovers?

Key House Republican on health care plans exit from Congress

Extreme heat events are a public health emergency

For Medicare Advantage, Democrats want stronger protections around AI

leisure time

entertainment

leisure time

At least 13 dead in Texas as scorching temps continue

Medical mystery: When a cough is not just a cough

Hollywood unions extend contract negotiations for actors

Private equity deals in Medicare Advantage declines

After affirmative action ruling, medical educators look to 'holistic review'

10 million people disenrolled from Medicaid over past six months

What does generative AI mean for health care? We asked experts

The dental labor crisis is a moment of opportunity

Alkermes shareholders re

Why did Pfizer dish out millions for a Super Bowl ad?

focus

HPV cancer vaccine study demonstrates efficacy

Medical mystery: When a cough is not just a cough

HPV cancer vaccine study demonstrates efficacy

'Revelatory' study finds a smoking impact that remains after quitting

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

leisure time

focus

hotspot

focus